慢性免疫性血小板减少性紫癜(ITP)的血小板计数很低,目前的治疗方法是使用皮质激素、免疫球蛋白或脾切除术。2008年8月20日美国FDA批准上市、由美国Amgen公司生产的新药罗米司亭(romiplostim,商品名:Nplate),是用于血小板减少症的第一个骨髓刺激剂,是在上述方法无效时的又一选择[1]。 Chronic immune thrombocytopenic purpura (ITP) platelet count is very low, the current treatment is the use of corticosteroids, immunoglobulins or splenectomy. August 20, 2008 US FDA Approves New Drug Romiplostim (Trade Name: Nplate), a new drug produced by Amgen Corporation in the United States, is the first bone marrow stimulator used in thrombocytopenia and is ineffective in the above method Another time of choice [1].